Literature DB >> 9792651

Identification of residues responsible for the selective binding of peptide antagonists and agonists in the V2 vasopressin receptor.

N Cotte1, M N Balestre, S Phalipou, M Hibert, M Manning, C Barberis, B Mouillac.   

Abstract

To improve our understanding of the functional architecture of G protein-coupled receptors, we have taken advantage of differences among mammalian species in ligand binding to search for the rat versus human selectivity determinants of the V2 vasopressin receptor and of its peptide ligands. Our data indicate that residue 2 of species-selective peptide antagonists such as d(CH2)5-[D-Ile2,Ile4, Tyr-NH29]arginine vasopressin controls their rat versus human selectivity. For species-selective agonists such as desmopressin, residues 1 and 8 modulate the binding selectivity. Among residues different between rat and human V2 receptors, those localized in the upper part of the human V2 receptor have been substituted with their rat V2 homologs. Pharmacological analysis of mutant receptors revealed that residues 202 and 304 fully control the species selectivity of the discriminating antagonists in an independent and additive manner. A third residue (position 100) is necessary to observe an equivalent phenomenon for the discriminating agonists. The substitution of these three residues does not modify the affinity of the nonselective agonists and antagonists. In conclusion, extracellular loops and the top of the transmembrane domains of V2 vasopressin receptors may provide the molecular basis for peptide ligand-binding species selectivity. Very few residues in these regions may control the binding mode of both agonists and antagonists.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9792651     DOI: 10.1074/jbc.273.45.29462

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Time-resolved FRET between GPCR ligands reveals oligomers in native tissues.

Authors:  Laura Albizu; Martin Cottet; Michaela Kralikova; Stoytcho Stoev; René Seyer; Isabelle Brabet; Thomas Roux; Hervé Bazin; Emmanuel Bourrier; Laurent Lamarque; Christophe Breton; Marie-Laure Rives; Amy Newman; Jonathan Javitch; Eric Trinquet; Maurice Manning; Jean-Philippe Pin; Bernard Mouillac; Thierry Durroux
Journal:  Nat Chem Biol       Date:  2010-07-11       Impact factor: 15.040

2.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

3.  Regulation of renal urea transport by vasopressin.

Authors:  Jeff M Sands; Mitsi A Blount; Janet D Klein
Journal:  Trans Am Clin Climatol Assoc       Date:  2011

4.  Pharmacological characterization of F-180: a selective human V(1a) vasopressin receptor agonist of high affinity.

Authors:  Miriam Andrés; Miguel Trueba; Gilles Guillon
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

5.  Receptor antagonism/agonism can be uncoupled from pharmacoperone activity.

Authors:  Jo Ann Janovick; Timothy P Spicer; Emery Smith; Thomas D Bannister; Terry Kenakin; Louis Scampavia; P Michael Conn
Journal:  Mol Cell Endocrinol       Date:  2016-07-04       Impact factor: 4.102

6.  Postnatal expression of V2 vasopressin receptor splice variants in the rat cerebellum.

Authors:  Karina J Vargas; José M Sarmiento; Pamela Ehrenfeld; Carolina C Añazco; Carolina I Villanueva; Pamela L Carmona; Marianne Brenet; Javier Navarro; Werner Müller-Esterl; Carlos B González
Journal:  Differentiation       Date:  2009-01-20       Impact factor: 3.880

Review 7.  Human kidney cell reprogramming: applications for disease modeling and personalized medicine.

Authors:  Adam C O'Neill; Sharon D Ricardo
Journal:  J Am Soc Nephrol       Date:  2013-08-15       Impact factor: 10.121

8.  Molecular evolution of the neuropeptide S receptor.

Authors:  Thejkiran Pitti; Narayanan Manoj
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240

9.  In vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V1 and V2.

Authors:  Khurram Jamil; Stephen Chris Pappas; Krishna R Devarakonda
Journal:  J Exp Pharmacol       Date:  2017-12-20

10.  Peptide Agonists of Vasopressin V2 Receptor Reduce Expression of Neuroendocrine Markers and Tumor Growth in Human Lung and Prostate Tumor Cells.

Authors:  Marina Pifano; Juan Garona; Carla S Capobianco; Nazareno Gonzalez; Daniel F Alonso; Giselle V Ripoll
Journal:  Front Oncol       Date:  2017-01-30       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.